E “New Frontier Stocks” At Play In The Battle Against Ebola

The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA’s awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more that and constant media attention.

Several public companies like Inovio Pharmaceuticals Inc (NASDAQ:INO) and Hemispherx BioPharma (NYSEMKT:HEB) have thrown their hats into the ring to become part of the Ebola conversation, but Tekmira Pharmaceuticals (NASDAQ:TKMR) continues to perform well for investors day in and day out.

Actually, the developer of RNA interference (RNAi) therapeutics has become one of biotech’s best performing stocks since we first highlighted the firm as shares were trading at only $4.50, back in 2012.

TKMR shares had seen a steady increase in value since that time, but we’ve seen that growth reach new levels since the firm’s own TKM-EBOLA was cleared for emergency use against Ebola in West Africa.

The company has announced it will join an international consortium that will establish clinical development centers in Ebola hot zones and Maxim’s analyst Jason Kolbert said that his firm has accelerated their Ebola assumptions and as a result sees additional upside in the stock.

In a research report just released to investors, Kolbert reiterated a Buy rating on Tekmira and raised his price target to $31 from $23, as the company announced the achievement of a development milestone, supporting a $1.5 million payment from Monsanto, for work outside of the pandemic space.

That investors have taken notice of Tekmira during recent headline grabs is wonderful, but those have been following the company for any length of time will tell you that the firm’s true value lies in what most in the industry consider a clinically validated "gold standard" for RNA interference (RNAi) therapeutics delivery. 

While many experts have often said that "RNAi will revolutionize medicine" with its ability to turn off genes (thus enabling new drugs for dozens of diseases), the real challenge for the Nobel Prize winning technology has been delivery and that's where Tekmira shines.

1 2 3 4
View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
George Lipton 6 years ago Member's comment

Great article, any updates on these stocks?

Terry Chrisomalis 6 years ago Contributor's comment

Inovio Pharmaceuticals (INO) and Tekmira Pharmaceuticals (TKMR) both IMO have a bright future regardless of Ebola treatments. Although short term Tekmira will trade based off its ebola drug TKM-EBola and traders should be cautious if something goes wrong. But for Tekmira Investors regardless the company has an amazing future with its LNP technology platform.